sellModerate cluster of 310b5-1 plan
Patricia C Hirano sold $11M of SLNO
SEE REMARKS at SOLENO THERAPEUTICS INC. 156,315 shares at an average of $68.51, traded Mar 27, 2025, filed Mar 31, 2025.
Warning score
40Value
$11M
156,315 shares
Holdings after
30,818
-139% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$10.7M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-009291, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -1,418 | $65.97 | $94k | 110,884 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -2,310 | $66.79 | $154k | 108,574 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -4,199 | $67.70 | $284k | 104,375 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -5,524 | $68.79 | $380k | 98,851 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -3,198 | $69.84 | $223k | 95,653 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -329 | $70.73 | $23k | 95,324 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -478 | $71.74 | $34k | 94,846 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -73 | $72.64 | $5,303 | 94,773 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +6,000 | $24.00 | $144k | 100,773 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +4,400 | $25.05 | $110k | 105,173 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +4,888 | $5.10 | $25k | 110,061 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +13,333 | $2.60 | $35k | 123,394 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +8,333 | $2.41 | $20k | 131,727 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +35,186 | $5.25 | $185k | 166,913 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -46,214 | $66.39 | $3.1M | 120,699 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -24,776 | $67.47 | $1.7M | 95,923 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -24,989 | $70.18 | $1.8M | 70,934 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -15,145 | $72.50 | $1.1M | 55,789 | Mar 31, 2025 |
| Mar 28, 2025 | MOption exercise Common Stock10b5-1 | +2,691 | $33.60 | $90k | 58,480 | Mar 31, 2025 |
| Mar 28, 2025 | SOpen-market sale Common Stock10b5-1 | -3,394 | $67.46 | $229k | 55,086 | Mar 31, 2025 |
| Mar 28, 2025 | SOpen-market sale Common Stock10b5-1 | -12,324 | $68.92 | $849k | 42,762 | Mar 31, 2025 |
| Mar 28, 2025 | SOpen-market sale Common Stock10b5-1 | -9,253 | $69.52 | $643k | 33,509 | Mar 31, 2025 |
| Mar 28, 2025 | SOpen-market sale Common Stock10b5-1 | -2,691 | $73.60 | $198k | 30,818 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -4,400 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -4,888 | $0.00 | $0 | 2,445 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -13,333 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -8,333 | $0.00 | $0 | 11,667 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -35,186 | $0.00 | $0 | 49,262 | Mar 31, 2025 |
| Mar 28, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -2,691 | $0.00 | $0 | 18,842 | Mar 31, 2025 |
Related signals
Other insiders at SOLENO THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $200k 6,582 shares | -14% | |
| 41Moderate | SOLENO THERAPEUTICS INC | Meredith Manning Chief Commercial Officer | $229k 7,522 shares | -10% | |
| 14Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $317k 3,830 shares | -22% | |
| 0Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $22k 266 shares | -2% | |
| 28Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $265k 3,782 shares | -12% | |
| 70Notable | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $47M 699,095 shares | -93% | |
| 50Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $1.0M 14,583 shares | -35% | |
| 58Moderate | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $966k 21,091 shares | -3% | |
| 34Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $139k 3,030 shares | -3% | |
| 65Notable | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $1.1M 21,633 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.